Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by TT International Asset Management LTD

TT International Asset Management LTD cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 68.8% during the fourth quarter, Holdings Channel reports. The firm owned 4,675 shares of the biopharmaceutical company’s stock after selling 10,325 shares during the period. TT International Asset Management LTD’s holdings in Gilead Sciences were worth $431,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at about $25,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the second quarter worth about $33,000. Cedar Wealth Management LLC boosted its stake in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the last quarter. Finally, Friedenthal Financial purchased a new stake in shares of Gilead Sciences in the third quarter worth about $50,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 8,500 shares of Gilead Sciences stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the sale, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at $12,173,021.08. The trade was a 6.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 453,734 shares of company stock valued at $41,902,086 over the last quarter. 0.16% of the stock is owned by insiders.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $89.88 on Monday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market cap of $112.01 billion, a PE ratio of 998.67, a P/E/G ratio of 2.24 and a beta of 0.18. The stock has a 50 day moving average price of $91.94 and a 200 day moving average price of $83.39.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter last year, the firm earned $2.29 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.43%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on GILD shares. Wells Fargo & Company upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Robert W. Baird upped their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, The Goldman Sachs Group increased their price target on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.